Biogen Amevive review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biogen's Amevive (alefacept) will come before FDA Dermatologic & Ophthalmic Drugs Advisory Committee May 13. Biogen submitted the BLA in August 2001 for treatment of moderate to severe chronic plaque psoriasis in patients who are candidates for phototherapy or systemic therap
Biogen's Amevive (alefacept) will come before FDA Dermatologic & Ophthalmic Drugs Advisory Committee May 13. Biogen submitted the BLA in August 2001 for treatment of moderate to severe chronic plaque psoriasis in patients who are candidates for phototherapy or systemic therapy |